NanoVibronix, Inc. (NAOV)
NASDAQ: NAOV · Real-Time Price · USD
4.350
+0.050 (1.16%)
At close: May 5, 2025, 4:00 PM
4.170
-0.180 (-4.14%)
Pre-market: May 6, 2025, 5:33 AM EDT
NanoVibronix Revenue
In the year 2024, NanoVibronix had annual revenue of $2.56M with 12.05% growth. NanoVibronix had revenue of $444.00K in the quarter ending December 31, 2024, a decrease of -62.28%.
Revenue (ttm)
$2.56M
Revenue Growth
+12.05%
P/S Ratio
0.46
Revenue / Employee
$82,516
Employees
31
Market Cap
3.30M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 2.56M | 275.00K | 12.05% |
| Dec 31, 2023 | 2.28M | 1.53M | 203.59% |
| Dec 31, 2022 | 752.00K | -943.00K | -55.63% |
| Dec 31, 2021 | 1.70M | 1.07M | 172.07% |
| Dec 31, 2020 | 623.00K | 93.00K | 17.55% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 410.06B |
| Johnson & Johnson | 89.33B |
| Merck & Co. | 63.92B |
| AbbVie | 57.37B |
| AstraZeneca | 54.98B |
| Novartis AG | 53.22B |
| Eli Lilly and Company | 49.00B |
| Thermo Fisher Scientific | 42.90B |
NAOV News
- 24 days ago - NanoVibronix Regains Nasdaq Compliance - Business Wire
- 4 weeks ago - NanoVibronix Announces Renewal and Expansion of Distribution Agreement with Dukehill Healthcare Pty Ltd in Australia - Business Wire
- 7 weeks ago - Successful Independent Study of the NanoVibronix UroShield® Device Published in the Australian and New Zealand Continence Journal - Business Wire
- 7 weeks ago - NanoVibronix Announces Reverse Stock Split - Business Wire
- 2 months ago - NanoVibronix, Inc. Announces Acquisition of ENvue Medical Holdings, Corp. - Business Wire
- 4 months ago - NanoVibronix Advances Development of PainShield and UroShield with Completion of NextGen Prototypes - Business Wire
- 4 months ago - NanoVibronix Announces Completion of Pilot Phase of Clinical Study of UroShield® at the University of Michigan - Business Wire
- 5 months ago - NanoVibronix Secures $12 Million Minimum Purchase Commitment for PainShield with Extension of Distribution Agreement - Business Wire